RS60697B1 - Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta - Google Patents

Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta

Info

Publication number
RS60697B1
RS60697B1 RS20200901A RSP20200901A RS60697B1 RS 60697 B1 RS60697 B1 RS 60697B1 RS 20200901 A RS20200901 A RS 20200901A RS P20200901 A RSP20200901 A RS P20200901A RS 60697 B1 RS60697 B1 RS 60697B1
Authority
RS
Serbia
Prior art keywords
pyridin
methanone
ethylimidazo
hydroxyphenyl
substituted
Prior art date
Application number
RS20200901A
Other languages
English (en)
Serbian (sr)
Inventor
Dongfang Shi
Changjin Fu
Xi Cheng
Jianghua Zhu
Jie Wen
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co Ltd
Publication of RS60697B1 publication Critical patent/RS60697B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/06Antigout agents, e.g. antihyperuricemic or uricosuric agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RS20200901A 2015-09-10 2016-09-08 Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta RS60697B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
PCT/CN2016/098468 WO2017041732A1 (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物
EP16843670.7A EP3348557B1 (en) 2015-09-10 2016-09-08 Imidazo[1,2a]pyridines for treating or preventing hyperuricemia or gout

Publications (1)

Publication Number Publication Date
RS60697B1 true RS60697B1 (sr) 2020-09-30

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20200901A RS60697B1 (sr) 2015-09-10 2016-09-08 Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta

Country Status (27)

Country Link
US (1) US10399971B2 (https=)
EP (1) EP3348557B1 (https=)
JP (1) JP6635527B2 (https=)
KR (1) KR102109061B1 (https=)
CN (1) CN106432229B (https=)
AU (1) AU2016320073B2 (https=)
BR (1) BR112018004863B1 (https=)
CA (1) CA2998034C (https=)
CY (1) CY1123137T1 (https=)
DK (1) DK3348557T3 (https=)
EA (1) EA037280B1 (https=)
ES (1) ES2803223T3 (https=)
HR (1) HRP20201094T1 (https=)
HU (1) HUE051448T2 (https=)
IL (1) IL257960A (https=)
LT (1) LT3348557T (https=)
MX (1) MX375068B (https=)
MY (1) MY195675A (https=)
NZ (1) NZ741318A (https=)
PL (1) PL3348557T3 (https=)
PT (1) PT3348557T (https=)
RS (1) RS60697B1 (https=)
SG (1) SG11201802010QA (https=)
SI (1) SI3348557T1 (https=)
TW (1) TWI681772B (https=)
WO (1) WO2017041732A1 (https=)
ZA (1) ZA201802312B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
CN108084186B (zh) * 2016-11-16 2021-06-25 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
EP3632904B1 (en) * 2017-05-26 2022-04-20 Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. Urat1 inhibitors for promoting uric acid excretion
CN114213331B (zh) * 2017-05-26 2024-06-21 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
CN112979661B (zh) * 2018-01-19 2022-05-17 苏州信诺维医药科技股份有限公司 杂环化合物、制备方法及其在医药上的应用
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
CN113717072A (zh) * 2021-09-28 2021-11-30 铜仁百朗制药有限公司 一种治疗便秘药物中间体的制备方法
CN116715633B (zh) * 2022-04-27 2025-08-12 杭州新元素药业股份有限公司 可用于降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout
TWI898321B (zh) * 2023-11-17 2025-09-21 大陸商杭州新元素藥業有限公司 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
WO2025237171A1 (zh) * 2024-05-11 2025-11-20 广州市联瑞制药有限公司 嘧啶并五元氮杂环酚类化合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2647451B1 (fr) 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
US10005750B2 (en) * 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
WO2014017643A1 (ja) * 2012-07-27 2014-01-30 佐藤製薬株式会社 ジフルオロメチレン化合物

Also Published As

Publication number Publication date
SI3348557T1 (sl) 2020-09-30
HRP20201094T1 (hr) 2020-10-30
ZA201802312B (en) 2024-11-27
CN106432229A (zh) 2017-02-22
DK3348557T3 (da) 2020-07-20
AU2016320073A1 (en) 2018-04-26
CA2998034C (en) 2021-05-04
BR112018004863B1 (pt) 2023-04-18
JP6635527B2 (ja) 2020-01-29
CN106432229B (zh) 2018-01-12
SG11201802010QA (en) 2018-04-27
EA201890694A1 (ru) 2018-10-31
KR20180044426A (ko) 2018-05-02
MX2018003006A (es) 2018-08-09
US10399971B2 (en) 2019-09-03
HUE051448T2 (hu) 2021-03-01
MX375068B (es) 2025-03-06
TW201808284A (zh) 2018-03-16
CA2998034A1 (en) 2017-03-16
ES2803223T3 (es) 2021-01-25
TWI681772B (zh) 2020-01-11
US20180282321A1 (en) 2018-10-04
EP3348557A1 (en) 2018-07-18
KR102109061B1 (ko) 2020-05-11
IL257960A (en) 2018-05-31
AU2016320073B2 (en) 2019-05-09
EP3348557A4 (en) 2019-03-06
JP2018526417A (ja) 2018-09-13
EP3348557B1 (en) 2020-04-29
BR112018004863A2 (https=) 2018-10-02
PT3348557T (pt) 2020-08-03
CY1123137T1 (el) 2021-10-29
PL3348557T3 (pl) 2020-11-16
NZ741318A (en) 2019-03-29
LT3348557T (lt) 2020-08-10
WO2017041732A1 (zh) 2017-03-16
EA037280B1 (ru) 2021-03-03
MY195675A (en) 2023-02-03

Similar Documents

Publication Publication Date Title
RS60697B1 (sr) Imidazo[1,2-a]piridini za lečenje ili prevenciju hiperurikemije ili gihta
ES2750309T3 (es) Nuevos derivados de arilamida que tienen propiedades antiandrogénicas
JP2020503263A (ja) Urat1抑制剤及びその使用
CN107683282B (zh) Urat1抑制剂及其在医药上的应用
TW200410675A (en) An NF-κB activation inhibitor
US10927085B2 (en) 1,2-naphthoquinone based derivative and method of preparing the same
Mourad et al. Enhancing insulin sensitivity by dual PPARγ partial agonist, β-catenin inhibitor: Design, synthesis of new αphthalimido-o-toluoyl2-aminothiazole hybrids
KR102329486B1 (ko) 할로겐화 화합물 및 이의 축상 키랄성 이성질체
WO2018189679A1 (en) Isoindoline derivatives for use as ampk activators
EP3735404B1 (en) Ask1 inhibitor compounds and uses thereof
CN107759588A (zh) 一类苯基‑(吡唑并[1,5‑a]吡啶‑3‑基)甲酮衍生物
CN112601734A (zh) 肟基萘醌类化合物及其制备方法和用途
JP2015160847A (ja) 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN104066717B (zh) 具有抗雄激素性质的新型杂芳基酰胺衍生物
CN104352497B (zh) 一种苯甲酰胺类化合物在制备抗肝癌药物中的应用
JP2008106017A (ja) Oatp選択的阻害性を有する化合物、及び該化合物を含むoatpの選択的阻害剤
WO2013104831A1 (en) Arylamide derivatives having antiandrogenic properties
HK1201838B (en) Novel heteroarylamide derivatives having antiandrogenic properties